Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREVAIL platform study in chronic hepatitis B infection
2022-002014-16Phase 2Active
- Sponsor
- Vir Biotechnology
- Start
- Dec 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of elebsiran in Chronic Hepatitis B (CHB) (3 arms), sponsored by Vir Biotechnology. Primary endpoint: Sustained suppression of HBV DNA. Started Dec 2022; status: active.
02
Drugs
elebsiran
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2022-002014-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002014-16.